After treatment with tested substances in multi-well plates, high content screening (HCS) or automated microscope-based screening detects biological activity in cells or entire organisms. Various methods for analyzing whole cells or cell components are included in the high content screening. Typically, one or more fluorescent dyes are used to measure several aspects of the cell or organism.
Our scientists have access to the Image Xpress Ultra from Molecular Devices Corporation in addition to the CellInsight CX5 platform we developed in-house. These tools can be used to perform a variety of assays, as indicated in the examples below.
Based on the degree of staining within the nucleus, this assay uses a nuclear strain to detect the cell cycle position of each cell. It can be employed in assays for cell viability, apoptosis, and mitosis.
We can make inferences about the biological implications of translocation of these molecules in the cell by establishing the location of a receptor, protein, or molecule of interest in treated.
Cell movement induce a localized rise in fluorescent protein content. It can be detected using this kind of investigation. Highly luminous granules reveal the concentration of tis protein in exceedingly specific sites in cells.
This assay determines the condition of each cell using many wavelengths, then scores each wavelength against other wavelengths depending on size, shape, and position.
The CellInsight CX5 HCS Platform uses proprietary autofocus and integrated plate scanning intelligence technologies to examine cell populations and phenotypes.
The Ultra is a real point scanning confocal microscope that captures images at a higher resolution than the Micro. It contains four solid-state lasers with excitation wavelengths ranging from 405 to 633 nm.
Dual reporter assays, nuclear translocation, cytosol to plasma membrane translocation, genotoxicity screening, and morphological metrics such as cell shape, morphology, and target distribution alterations are just a few of the HCS we offer to help with drug discovery. The HCS platform can be utilized for a variety of purposes, including primary screening, secondary screening, and toxicity testing.
For high content screens, where the readout is based on pictures obtained by our patent high throughput microscopy technology, we provide assay development, screening, and data analysis/mining expertise and services. Our HCS team specializes in sample preparation, picture acquisition, image analysis, image data management, and algorithm development for high-content image-based screens.
Comfortable with any model
Any target, any label
Images into insights
Our team can assist you choose the proper cell type and assay settings before starting HCS, thanks to their considerable experience in high-throughput screening, in-house image analysis algorithm design, and disease biology.
HCA has advanced to encompass multicellular structures like 3D spheroids and co-cultures, as well as multiplexing to monitor various features within a microenvironment in a single well.
High-resolution imaging is a potent tool for drug development, but its implementation necessitates specialized equipment and knowledge that only a few companies have on hand.
We provides a comprehensive range of High Content Screening (HCS) services to clients using 3D cell models and classic cell-based assays, as experts in High Content Imaging and confocal microscopy, in our assays, and 3D cell culture models. Our team of professionals at Eicra is here to guide your team through every stage of the high-content screening process. Our team is highly flexible in how we work with clients, delivering a wide menu of validated in vitro screening services as well as speedy bespoke assay creation (3-4 week turnaround time).
No client is too big or too little for us: we provide target validation, bespoke assay creation, and end-to-end compound screening services to small pharma businesses. We also assist major pharmaceutical companies in the construction of high-content screening workflows and specialized image processing pipelines for on-site use in larger screening operations.
We collaborate extensively with our clients to define a project’s specific requirements. We offer small-scale proof-of-concept work for unique projects to demonstrate our skills and give you peace of mind that your screening campaigns are in excellent hands. To discuss your HCS requirements, please contact us directly.
You can utilize high content analysis to monitor compounds in complicated cellular systems to forecast translational success as you progress your candidate through lead optimization.
Over the last five years, the use of 3D cell culture models in drug screening has risen at an exponential rate. We understand the value of 3D cell culture because of its better in vivo relevance and inexpensive cost. 3D cell culture is rapidly evolving and changing as a plethora of models, lines, media, and matrices are embraced across the industry, each with its own set of benefits and limitations.
From microtissues to prostate biopsies, rabbit retinas, and complete owl brains, our team of professionals has worked on a wide range of projects. We’ve created a reliable process for optimizing and validating new targets, and when combined with our expertise in high-resolution imaging, we can quantify almost any target with almost any label.
Drug development is a fast-paced process, and high-content screening was designed to keep up. To speed up high-content screening, our team employs automation, computerization, and robotics. Three to four weeks is a typical turnaround time for three-color assays. Before moving on to larger screens for specific projects, we start with a low-cost proof of concept to demonstrate our competence.
A typical HCS test can potentially generate over 100,000 pictures, creating a significant bottleneck in data processing and analysis. We quickly filter through tens of thousands of photos to extract quantitative data, collecting cell counts, morphological features, label colocalization, and performing statistical comparisons across groups using our custom-built image processing pipeline.
In high content screening, cells are first incubated with the material, then their structures and molecular components are examined after a period of time. The most popular method includes marking proteins with fluorescent tags, followed by automated picture processing to measure changes in cell phenotypic.
The results are sent to you through email or by API connection and loaded straight into your system/application. Optionally, you will be given access to an AWS server where your results will be uploaded and accessed.
Our online ordering system will be updated with the results. When the reports are finished, you will receive an email.
Negative drug testing findings will take around 24 hours to arrive at the laboratory, while non-negative results will take an additional 24-72 hours (due to additional confirmation). If non-negative findings are provided through the Medical Review procedure, the MRO will need to call the donor and confirm the outcome for a further 24-72 hours.